Gilead Sciences, Inc (NASDAQ:GILD) has a beta value of 0.31 and has seen 1.18 million shares traded in the recent trading session. The company, currently valued at $132.84B, closed the recent trade at $9410000.0 per share which meant it gained $9409891.5 on the day or 1180855% during that session. The GILD stock price is 100.0% off its 52-week high price of $119.96 and 100.0% above the 52-week low of $66.01. If we look at the company’s 10-day average daily trading volume, we find that it stood at 9.02 million shares traded. The 3-month trading volume is 9.41 million shares.
The consensus among analysts is that Gilead Sciences, Inc (GILD) is Buy stock at the moment, with a recommendation rating of 1.87. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 17 have rated it as a Hold, with 11 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 1.95.
Gilead Sciences, Inc (NASDAQ:GILD) trade information
Over the past 30 days, the shares of Gilead Sciences, Inc (NASDAQ:GILD) have changed -0.86%. Short interest in the company has seen 20.94 million shares shorted with days to cover at 2.39.
Wall Street analysts have a consensus price target for the stock at $126, which means that the shares’ value could drop -7468153.97% from the levels at last check today.. The projected low price target is $83.0 while the price target rests at a high of $135.0. In that case, then, we find that the latest price level in today’s session is 100.0% off the targeted high while a plunge would see the stock lose 100.0% from the levels at last check today..
Gilead Sciences, Inc (GILD) estimates and forecasts
The company’s shares have gained 15.08% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -0.28%.
19 analysts offering their estimates for the company have set an average revenue estimate of 6.95B for the current quarter. 18 have an estimated revenue figure of 7.39B for the next ending quarter. Year-ago sales stood 6.95B and 7.54B respectively for this quarter and the next, and analysts expect sales will grow by 0.01% for the current quarter and -0.28% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -38.13% over the past 5 years. Earnings growth for 2025 is a modest 72.50% while over the next 5 years, the company’s earnings are expected to increase by 26.05%.
GILD Dividends
Gilead Sciences, Inc is expected to release its next earnings report on 2025-Apr-24 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 3.12 at a share yield of 2.92%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 3.96%.
Gilead Sciences, Inc (NASDAQ:GILD)’s Major holders
Insiders own 0.12% of the company shares, while shares held by institutions stand at 89.70% with a share float percentage of 89.81%. Investors are also buoyed by the number of investors in a company, with Gilead Sciences, Inc having a total of 2731.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 120.63 million shares worth more than $8.28 billion. As of 2024-06-30, BLACKROCK INC. held 9.6738% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 115.26 million shares as of 2024-06-30. The firm’s total holdings are worth over $7.91 billion and represent 9.2431% of shares outstanding.
